# Rh-Associated Glycoprotein Blood Group System

### Number of antigens 4

Low prevalence Ola, RHAG4

High prevalence Duclos, DSLK (Duclos-like)

## **Terminology**

ISBT Symbol (number) RHAG (030) CD number CD241

History RhAG was elevated to a blood group system in 2008

when the molecular basis of Duclos, Ola, and DSLK were determined to be due to nucleotide changes in

RHAG.

# **Expression**

Cord RBCs Expressed
Tissues RhAG homologs

#### Gene

Chromosome 6p21.3 Name *RHAG* 

Organization 10 exons distributed over 32 kbp of DNA Product Rh-associated glycoprotein (RhAG)



### **Database accession numbers**

GenBank X64594 (mRNA); NG\_011704 (gene); NM\_000324

(mRNA)

Entrez Gene ID 6005

### Molecular basis of Rh-associated glycoprotein antigens<sup>1</sup>

Reference allele, *RHAG\*01* (Accession number X64594) encodes Duclos (RHAG1), RHAG3. Differences from this allele are given.

Allele encodes	Allele name	Exon	Nucleotide	Amino acid	Ethnicity (prevalence)	
Duclos- or RHAG:-1	RHAG*-01	2	316C>G	Gln106Glu	(Rare)	
Ol(a+) or RHAG:2	RHAG*01.02	5	680C>T^	Ser227Leu	Norwegian, Japanese (Several)	
DSLK- or RHAG:-3	RHAG*0103	3	490A>C	Lys164Gln	(Rare)	
RHAG:4	RHAG*01.04	6	808G>A	Val270Ile	(Rare)	
^= Homozygosity for <i>RHAG*01.02</i> encodes an Rh <sub>mod</sub> phenotype.						

# Molecular bases of silencing of RHAG

Homozygosity and compound heterozygosity leads to regulator Rh<sub>null</sub> phenotype.

Assignment of null (*N*) alleles has been made (by the ISBT working party) according to the lack of phenotypic expression of RhD and RhCE antigens or lack of reactivity with monoclonal anti-RhAG (e.g., 2D10, L18.18). Differences from *RHAG\*01* reference allele (Accession number X64594) are given.

Allele name	Exon (intron)	Nucleotide	Restriction enzyme	Amino acid	Ethnicity (prevalence)
RHAG*01N.01	2	154–157CCTC>GA	Mn/I–	Tyr51fs, Ile107Stop	South African (Rare)
RHAG*01N.02	8	1086delA	Pvull–	Ala362fs, Val374Stop	(Rare)
RHAG*01N.03	Intron 1	IVS1+1g>a		Alternative splicing	White American (Rare)
RHAG*01N.04	Intron 6	IVS6+1g>a		Alternative splicing <sup>2</sup>	(Rare)
RHAG*01N.05	Intron 6	IVS6-1g>a		Alternative splicing	Spanish (Rare)
RHAG*01N.06	Intron 6	IVS6-1g>t		Alternative splicing	Japanese (Rare)
RHAG*01N.07	Intron 7	IVS7+1g>a	Pm/I–	Alternative splicing	Japanese (Rare)
RHAG*01N.08	6	808G>A^ 838G>A		Val270Ile Gly280Arg	Japanese (Rare)
RHAG*01N.09	6	836G>A	Mnll–	Gly279Glu	Australian (English/ French, Irish/Scottish) (Rare)
RHAG*01N.10	8	1094T>G		Leu365Arg <sup>2</sup>	(Rare)
RHAG*01N.11	9	1139G>T		Gly380Val + alternative splicing	Japanese (Rare)
RHAG*01N.12	5	762C>A		Ser224Arg <sup>3</sup>	Chinese (Rare)

See Rh blood group system for molecular bases of amorph  $Rh_{null}$  phenotype. ^= This single change encodes RHAG:4.

# KHAG

# Molecular bases of weak Rh-Associated Glycoprotein antigens

Homozygosity, compound heterozygosity, or heterozygosity for RHAG\*01M.08 or RHAG\*01M.09 leads to  $Rh_{mod}$  phenotype.

Assignment of mod (M) alleles has been made (by the ISBT working party) according to the weak phenotypic expression of RhD and RhCE antigens or depressed RhAG.

Differences from *RHAG\*01* reference allele (Accession number X64594) are given.

Allele name	Exon	Nucleotide	Amino acid	Ethnicity (prevalence)
RHAG*01M.01	9	1183delA	Asn395fs + 52 additional amino acids	Japanese (Rare)
RHAG*01M.02	1	3G>T	Met1Ile	Jewish Russian (Rare)
RHAG*01M.03	2	236G>A	Ser79Asn	Caucasian (Rare)
RHAG*01M.04	2	269G>T	Gly90Val <sup>4</sup>	(Rare)
RHAG*01M.05	3	398T>C	Leu133Pro <sup>5#</sup>	(Rare)
RHAG*01M.06	4	560G>A	Gly187Asp <sup>4</sup>	(Rare)
RHAG*01M.07	9	1195G>T	Asp399Tyr	French (Rare)
RHAG*01M.08	2	182T>G	Ile61Arg	(Rare)
RHAG*01M.09	2	194T>C	Phe65Ser	(Few)
RHAG*01.02^	5	680C>T^	Ser227Leu	Japanese

 $<sup>\ ^{\</sup>smallfrown}=$  Homozygosity causes a  $Rh_{mod}$  phenotype. This allele encodes the  $Ol^{a}$  antigen.


## Amino acid sequence

MRFTFPLMAI	VLEIAMIVLF	GLFVEYETDQ	TVLEQLNITK	PTDMGIFFEL	50
YPLFQDVHVM	IFVGFGFLMT	FLKKYGFSSV	GINLLVAALG	LQWGTIVQGI	100
LQSQGQKFNI	GIKNMINADF	SAATVLISFG	AVLGKTSPTQ	MLIMTILEIV	150
FFAHNEYLVS	EIFKASDIGA	SMTIHAFGAY	FGLAVAGILY	RSGLRKGHEN	200
EESAYYSDLF	AMIGTLFLWM	FWPSFNSAIA	EPGDKQCRAI	VDTYFSLAAC	250
VLTAFAFSSL	VEHRGKLNMV	HIQNATLAGG	VAVGTCADMA	IHPFGSMIIG	300
SIAGMVSVLG	YKFLTPLFTT	KLRIHDTCGV	HNLHGLPGVV	GGLAGIVAVA	350
MGASNTSMAM	QAAALGSSIG	TAVVGGLMTG	LILKLPLWGQ	PSDQNCYDDS	400
VYWKVPKTR					409

<sup>#=</sup> In the abstract 133 is, incorrectly, given as Arg.

#### Carrier protein

A multipass membrane glycoprotein.



 $M_{\rm r}$  (SDS-PAGE) 45,000 to 100,000 with a predominant band of

50,000

CHO: N-glycan 1 (plus 1 potential site)

Cysteine residues

Copies per RBC 100,000–200,000

#### **Function**

RhAG forms a core complex with RhD and/or RhCE. This complex is also associated with GPB, LW, and CD47, which in turn is associated with the band 3/GPA complex that links to the RBC membrane skeleton via ankyrin and protein 4.2. This complex maintains erythrocyte membrane integrity, as demonstrated by the abnormal morphology of stomatocytic  $Rh_{null}$  RBCs. Involved in  $NH_4^+/NH_3$  or  $CO_2/O_2$ , and cation transport across the membrane<sup>6</sup>.

#### Disease association

Compensated hemolytic anemia occurs in some individuals with regulator type Rh<sub>null</sub> or Rh<sub>mod</sub> RBCs. Over-hydrated stomatocytosis (OHSt) is associated with dominant mutations in RhAG: Phe65Ser (six families) and Ile61Arg (one family), and cation leak<sup>7</sup>.

#### Comments

RhAG is essential for expression of Rh antigens<sup>8</sup>.

#### References

<sup>1</sup> Tilley, L., et al., 2010. A new blood group system, RHAG: three antigens resulting from amino acid substitutions in the Rh-associated glycoprotein. Vox Sang 98, 151–159.

RHAG

- <sup>2</sup> Tsuneyama, H., et al., 2005. Identification of two new mutations in the RhAG gene of Japanese with Rh<sub>null</sub> phenotype [abstract]. Transfusion 45 (Suppl.), 130A.
- <sup>3</sup> Tian, L., et al., 2011. A family study of the Chinese Rh(null) individual of the regulator type: a novel single missense mutation identified in RHAG gene. Transfusion 51, 2686–2689.
- <sup>4</sup> Scharberg, A., et al., 2006. RHMOD phenotype caused by double heterozygosity for two new alleles of the RHAG gene [abstract]. Vox Sang 91 (Suppl. 3), 129.
- <sup>5</sup> Tsuneyama, H., et al., 2008. Identification of two new mutations in the RhAG gene of Japanese with Rh<sub>mod</sub> phenotype [abstract]. Transfusion 48 (Suppl.), 185A–186A.
- <sup>6</sup> Burton, N.M., Anstee, D.J., 2008. Structure, function and significance of Rh proteins in red cells. Curr Opin Hematol 15, 625–630.
- <sup>7</sup> Bruce, L.J., et al., 2009. The monovalent cation leak in overhydrated stomatocytic red blood cells results from amino acid substitutions in the Rh-associated glycoprotein. Blood 113, 1350–1357.
- <sup>8</sup> Huang, C.-H., et al., 2000. Molecular biology and genetics of the Rh blood group system. Semin Hematol 37, 150–165.

# **Duclos Antigen**

# **Terminology**

ISBT symbol (number) RHAG1 (030001 or 30.1)

History Identified in 1978. Mrs Duclos made an antibody to

a high-prevalence antigen that was non-reactive with

Rh<sub>null</sub> and U– RBCs.

#### Occurrence

Only one Duclos- proband has been reported.

### **Expression**

Cord RBCs Expressed

# Molecular basis associated with Duclos antigen<sup>1</sup>

Amino acid Gln106

Nucleotide C at bp 316 in exon 2 Duclos- Glu106 and G at bp 316

# Effect of enzymes and chemicals on Duclos antigen on intact RBCs

Ficin/Papain Resistant (enhanced)
Trypsin Resistant (enhanced)

α-Chymotrypsin Weakened

DTT 200 mM/50 mM Sensitive/resistant (thus sensitive to WARM<sup>TM</sup> and

ZZAP)

#### In vitro characteristics of alloanti-Duclos

Immunoglobulin class IgG Optimal technique IAT

## **Clinical significance of alloanti-Duclos**

No information is available because only one example of anti-Duclos has been described.

#### Comments

Duclos is absent from RBCs with either the U– Rh<sub>null</sub> or U– Rh<sub>mod</sub> phenotype.

#### Reference

# Ola Antigen

## **Terminology**

ISBT symbol (number) RHAG2 (030002 or 30.2)

Obsolete name Oldeide

History Identified in 1986 by screening random donors

with the multispecific serum Kirk. Named from the initials of the Ol(a+) index case whose C+c+

RBCs had a weak expression of C.

#### Occurrence

All populations <0.01%

#### **Expression**

Cord RBCs Presumed expressed

# Molecular basis associated with Ola antigen1

Amino acid Leu227

Nucleotide T at bp 680 in exon 5 Ol(a–) (wild type) Ser227 and C at bp 680

# Effect of enzymes and chemicals on Ola antigen on intact RBCs

Ficin/Papain Resistant (enhanced)

Trypsin Resistant

<sup>&</sup>lt;sup>1</sup> Tilley, L., et al., 2010. A new blood group system, RHAG: three antigens resulting from amino acid substitutions in the Rh-associated glycoprotein. Vox Sang 98, 151–159.

# RHAC

#### In vitro characteristics of alloanti-Ola

Immunoglobulin class IgG Optimal technique IAT

### Clinical significance of alloanti-Ola

No data because antigen is rare.

#### **Comments**

Homozygosity for RHAG\*01.02 encodes an Rh<sub>mod</sub> phenotype.

Ol(a+) RBCs have a weakened expression of Rh antigens (C and E) when *in trans* haplotype is informative.

#### Reference

# **DSLK Antigen**

#### **Terminology**

ISBT symbol (number) RHAG3 (030003 or 30.3)

History Identified in 1996 and named in 2010: "DS"

from "Duclos," and "LK" from "like" because the proband's RBCs were not agglutinated by the

Duclos plasma.

#### Occurrence

Only one DSLK– proband has been reported.

# **Expression**

Cord RBCs Presumed expressed

# Molecular basis associated with DSLK antigen<sup>1</sup>

Amino acid Lys164

Nucleotide A at bp 490 in exon 5 DSLK- Gln164 and C at bp 490

# Effect of enzymes and chemicals on DSLK antigen on intact RBCs

Ficin/Papain Resistant (enhanced)

Trypsin Resistant

<sup>&</sup>lt;sup>1</sup> Tilley, L., et al., 2010. A new blood group system, RHAG: three antigens resulting from amino acid substitutions in the Rh-associated glycoprotein. Vox Sang 98, 151–159.

#### In vitro characteristics of alloanti-DSLK

Immunoglobulin class IgG Optimal technique IAT

#### Clinical significance of alloanti-DSLK

No data because only one example of anti-DSLK has been described.

#### Comments

DSLK is absent from RBCs with either the U– Rh<sub>null</sub> or U– Rh<sub>mod</sub> phenotype.

#### Reference

# **RHAG4** Antigen

#### Terminology

ISBT symbol (number) RHAG4 (030004 or 30.4)

History Identified in 2011, when the antibody caused severe

HDFN.

#### Occurrence

The only antigen-positive proband was of African ancestry.

### **Expression**

Cord RBCs Expressed

# Molecular basis associated with RHAG4 antigen<sup>1</sup>

Amino acid Ile270

Nucleotide A at bp 808 in exon 6 RHAG – (wild type) Val270 and G at bp 808

# Effect of enzymes and chemicals on RHAG4 antigen on intact RBCs

Ficin/Papain Resistant (enhanced)

Trypsin Resistant

α-Chymotrypsin Presumed weakened

DTT 200 mM/50 mM Presumed sensitive/resistant (thus sensitive to

WARM<sup>TM</sup> and ZZAP)

<sup>&</sup>lt;sup>1</sup> Tilley, L., et al., 2010. A new blood group system, RHAG: three antigens resulting from amino acid substitutions in the Rh-associated glycoprotein. Vox Sang 98, 151–159.

#### In vitro characteristics of alloanti-RHAG4

Immunoglobulin class IgG Optimal technique IAT

# Clinical significance of alloanti-RHAG4

Transfusion reaction No data because antigen is rare

HDFN Severe<sup>1</sup>

#### Reference

<sup>1</sup> Poole, J., et al., 2011. A novel RHAG blood group antigen associated with severe HDFN [abstract]. Vox Sang 101 (Suppl. 1), 70.